GlaxoSmithKline LLC vs Philips North America: FDA Enforcement Comparison

Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 2 for GlaxoSmithKline LLC.

GlaxoSmithKline LLC: 0 warning letters, 2 recalls, 0 approval records, 0 Form 483s.

Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.

Side by side

GlaxoSmithKline LLC — Warning letters0

Philips North America — Warning letters0

GlaxoSmithKline LLC — Recalls2

Philips North America — Recalls355

GlaxoSmithKline LLC — Approval records0

Philips North America — Approval records0

GlaxoSmithKline LLC — Form 483s0

Philips North America — Form 483s0

Timeline

GlaxoSmithKline LLC

Most recent FDA action: June 12, 2024

Full history →

Philips North America

Most recent FDA action: July 1, 2026

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"GlaxoSmithKline LLC vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed July 17, 2026. https://argushq.ai/compare/glaxosmithkline-llc-vs-philips-north-america

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗